These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35154154)

  • 41. Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.
    López D
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape.
    Pretti MAM; Galvani RG; Scherer NM; Farias AS; Boroni M
    Infect Genet Evol; 2022 Apr; 99():105236. PubMed ID: 35149224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Systematic, Unbiased Mapping of CD8
    Stryhn A; Kongsgaard M; Rasmussen M; Harndahl MN; Østerbye T; Bassi MR; Thybo S; Gabriel M; Hansen MB; Nielsen M; Christensen JP; Randrup Thomsen A; Buus S
    Front Immunol; 2020; 11():1836. PubMed ID: 32983097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoinformatic approach to assess SARS-CoV-2 protein S epitopes recognised by the most frequent MHC-I alleles in the Brazilian population.
    Moura RR; Agrelli A; Santos-Silva CA; Silva N; Assunção BR; Brandão L; Benko-Iseppon AM; Crovella S
    J Clin Pathol; 2021 Aug; 74(8):528-532. PubMed ID: 32759312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Poluektov Y; George M; Daftarian P; Delcommenne MC
    Vaccine; 2021 Apr; 39(15):2110-2116. PubMed ID: 33744048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
    Almofti YA; Abd-Elrahman KA; Eltilib EEM
    BMC Immunol; 2021 Mar; 22(1):22. PubMed ID: 33765919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Nathan A; Rossin EJ; Kaseke C; Park RJ; Khatri A; Koundakjian D; Urbach JM; Singh NK; Bashirova A; Tano-Menka R; Senjobe F; Waring MT; Piechocka-Trocha A; Garcia-Beltran WF; Iafrate AJ; Naranbhai V; Carrington M; Walker BD; Gaiha GD
    Cell; 2021 Aug; 184(17):4401-4413.e10. PubMed ID: 34265281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
    Reche PA
    Front Immunol; 2020; 11():586984. PubMed ID: 33178220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
    Jung C; Kmiec D; Koepke L; Zech F; Jacob T; Sparrer KMJ; Kirchhoff F
    J Virol; 2022 Mar; 96(6):e0207721. PubMed ID: 35225672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Weingarten-Gabbay S; Klaeger S; Sarkizova S; Pearlman LR; Chen DY; Gallagher KME; Bauer MR; Taylor HB; Dunn WA; Tarr C; Sidney J; Rachimi S; Conway HL; Katsis K; Wang Y; Leistritz-Edwards D; Durkin MR; Tomkins-Tinch CH; Finkel Y; Nachshon A; Gentili M; Rivera KD; Carulli IP; Chea VA; Chandrashekar A; Bozkus CC; Carrington M; ; Bhardwaj N; Barouch DH; Sette A; Maus MV; Rice CM; Clauser KR; Keskin DB; Pregibon DC; Hacohen N; Carr SA; Abelin JG; Saeed M; Sabeti PC
    Cell; 2021 Jul; 184(15):3962-3980.e17. PubMed ID: 34171305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron.
    Mazzoni A; Vanni A; Spinicci M; Capone M; Lamacchia G; Salvati L; Coppi M; Antonelli A; Carnasciali A; Farahvachi P; Giovacchini N; Aiezza N; Malentacchi F; Zammarchi L; Liotta F; Rossolini GM; Bartoloni A; Cosmi L; Maggi L; Annunziato F
    Front Immunol; 2022; 13():801431. PubMed ID: 35154116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SARS-CoV-2 epitopes inform future vaccination strategies.
    Shafqat A; Omer MH; Ahmad O; Niaz M; Abdulkader HS; Shafqat S; Mushtaq AH; Shaik A; Elshaer AN; Kashir J; Alkattan K; Yaqinuddin A
    Front Immunol; 2022; 13():1041185. PubMed ID: 36505475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach.
    Hisham Y; Ashhab Y; Hwang SH; Kim DE
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33925069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.
    Rencilin CF; Rosy JC; Mohan M; Coico R; Sundar K
    Infect Genet Evol; 2021 Apr; 89():104712. PubMed ID: 33422682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
    Wu J; Nie J; Zhang L; Song H; An Y; Liang Z; Yang J; Ding R; Liu S; Li Q; Li T; Cui Z; Zhang M; He P; Wang Y; Qu X; Hu Z; Wang Q; Huang W
    Signal Transduct Target Ther; 2022 Jan; 7(1):18. PubMed ID: 35046385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
    Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
    J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.